HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
HUTCHMED Completes Patient Enrollment of a PhaseII Registration Study of SavolitinibinGastricCancer inChina
April 21, 2025 20:00 ET | Source: HUTCHMED (China) Limited HONG KONG…